IPP Bureau
Lupin receives approval from USFDA for Prasugrel Tablets, USP
By IPP Bureau - January 10, 2023
ProBioGen collaborates with Boehringer Ingelheim on DirectedLuck transposase technology
By IPP Bureau - January 10, 2023
The new project further expands the partner's long-term collaboration on new technologies for R&D
Suburban Diagnostics unveils Reference Laboratory in Mumbai
By IPP Bureau - January 09, 2023
The lab is also the first private lab in West India to have built its Mycobacteriology, Mycology, and Molecular Biology departments within a separate Bio Safety Level - 3 (BSL3) bio-containment lab
Dr. Mandaviya inaugurates Annex Building of ICMR-RMRC, Bhubaneswar
By IPP Bureau - January 09, 2023
The centre has initiated next generation sequencing (NGS) as a tool for undertaking studies on genomic epidemiology of pathogens
All AIIMS can transform into institutes of global excellence: Dr. Mandaviya
By IPP Bureau - January 09, 2023
He urged the dignitaries to collaboratively work on the identified domains of improvement and make detailed reports on them
AIIMS Bhubaneswar provides quality healthcare service in Eastern India: Dr Mandaviya
By IPP Bureau - January 09, 2023
Dr. Mandaviya and Dharmendra Pradhan dedicate Burns Centre at AIIMS; Lays foundation stone of Critical Care Hospital Building, and award 40 gold medals to meritorious students
Protein found in Zebrafish can regenerate aged discs in human vertebrae
By IPP Bureau - January 09, 2023
A study by Agharkar Research Institute (ARI), Pune, has discovered that a protein secreted from intervertebral disc cells induces disc regeneration in aged degenerated discs
KIMS invests further in Sarvejana Healthcare
By IPP Bureau - January 07, 2023
The company now holds 56.61% of the total paid-up equity share capital of Sarvejana Healthcare
Lupin receives approval from USFDA for Fesoterodine Fumarate Extended-Release Tablets
By IPP Bureau - January 07, 2023
Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, (RLD Toviaz®) had estimated annual sales of USD 177 million in the U.S. (IQVIA MAT September 2022).
Dabur India expects low to mid-single digit revenue growth for Q3 FY23
By IPP Bureau - January 07, 2023
International Business is expected to post double-digit revenue growth during the quarter in constant currency.
Zydus launches Topiramate Extended-Release Capsules
By IPP Bureau - January 07, 2023
Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.
Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets
By IPP Bureau - January 07, 2023
Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022
ANSSI Wellness inaugurates new spine health facility in Nashik
By IPP Bureau - January 07, 2023
ANSSI Wellness launches Asia’s premier and USA-patented ‘Spinal Decompression Treatment’ center in Nashik
Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma
By IPP Bureau - January 06, 2023
The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”
Helix and QIAGEN to jointly develop and commercialize companion diagnostics for hereditary diseases
By IPP Bureau - January 06, 2023
Partnership to leverage the Helix Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise
